Should I buy or sell Nektar Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares. View NKTR analyst ratings or view top-rated stocks .

What is Nektar Therapeutics' stock price target for 2024?

5 analysts have issued twelve-month target prices for Nektar Therapeutics' stock. Their NKTR share price targets range from $1.00 to $6.00. On average, they expect the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 182.3% from the stock's current price. View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts .

How have NKTR shares performed in 2024?

Nektar Therapeutics' stock was trading at $0.5650 at the start of the year. Since then, NKTR shares have increased by 119.5% and is now trading at $1.24. View the best growth stocks for 2024 here .

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our NKTR earnings forecast .

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) posted its earnings results on Monday, March, 4th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.01. The biopharmaceutical company had revenue of $23.89 million for the quarter, compared to analysts' expectations of $17.09 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 96.80% and a negative net margin of 306.31%. During the same quarter in the prior year, the business earned ($0.32) earnings per share.

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com . Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU) , NVIDIA (NVDA) , Alibaba Group (BABA) , Gilead Sciences (GILD) , Intel (INTC) , Pfizer (PFE) , Advanced Micro Devices (AMD) , Bristol-Myers Squibb (BMY) , Netflix (NFLX) and Incyte (INCY) .

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NKTR

Nektar Therapeutics (NKTR) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free NKTR Stock Alerts

$1.24

-0.08 (-6.06%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.20
▼
$1.33
50-Day Range: $0.66
▼
$1.67
52-Week Range: $0.41
▼
$1.75

Volume: 4.72 million shs
Average Volume: 2.20 million shs
Market Capitalization: $227.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.50

Get Nektar Therapeutics alerts:

Nektar Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 182.3% Upside
$3.50 Price Target
Short Interest: Healthy
1.32% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.77
Upright™ Environmental Score
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: Selling Shares
$19,752 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.93) to ($0.68) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.82 out of 5 stars

Medical Sector

209th out of 911 stocks

Pharmaceutical Preparations Industry

79th out of 410 stocks

3.0

Analyst's Opinion

Consensus Rating
Nektar Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Nektar Therapeutics has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.32% of the float of Nektar Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Nektar Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Nektar Therapeutics has recently decreased by 5.98%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Nektar Therapeutics does not currently pay a dividend.
Dividend Growth
Nektar Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Nektar Therapeutics has received a 60.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topoisomerase 1 (TOP1) inhibitors", "Clinical research services", and "Peripheral opioid receptor antagonists" products. See details.
Environmental Sustainability
The Environmental Impact score for Nektar Therapeutics is -1.77.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Nektar Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 15 people have searched for NKTR on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,752.00 in company stock.
Percentage Held by Insiders
Only 3.07% of the stock of Nektar Therapeutics is held by insiders.
Percentage Held by Institutions
75.88% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Nektar Therapeutics are expected to grow in the coming year, from ($0.93) to ($0.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nektar Therapeutics is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nektar Therapeutics is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nektar Therapeutics has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Nektar Therapeutics Stock (NASDAQ:NKTR)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

NKTR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NKTR Stock News Headlines

April 20, 2024 | investing.com

Nektar regains Nasdaq compliance with bid price

April 16, 2024 | americanbankingnews.com

Nektar Therapeutics (NASDAQ:NKTR) Stock Price Passes Above Two Hundred Day Moving Average of $0.65

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 10, 2024 | seekingalpha.com

Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test

March 29, 2024 | yahoo.com

“A fascinating listen that sometimes sounds like a missing 10cc album plus a little Be Box Deluxe”: Nektar’s Recycled 5CD set

March 22, 2024 | prnewswire.com

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

March 5, 2024 | finance.yahoo.com

Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript

March 5, 2024 | finance.yahoo.com

Q4 2023 Nektar Therapeutics Earnings Call

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 5, 2024 | prnewswire.com

Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

March 4, 2024 | markets.businessinsider.com

Nektar Therapeutics Q4 Loss decreases, but misses estimates

March 4, 2024 | finance.yahoo.com

Nektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Results

March 4, 2024 | prnewswire.com

Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results

March 4, 2024 | markets.businessinsider.com

Nektar Therapeutics Announces $30 Mln Private Placement Financing With TCGX; Stock Up In Premarket

March 4, 2024 | prnewswire.com

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX

March 3, 2024 | markets.businessinsider.com

Nektar Therapeutics earnings: here's what Wall Street expects

March 1, 2024 | benzinga.com

Nektar Therapeutics Earnings Preview

February 27, 2024 | prnewswire.com

Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference

February 26, 2024 | prnewswire.com

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets

February 23, 2024 | msn.com

Nektar to play final UK live show at Nene Valley Rock festival in September

February 22, 2024 | msn.com

Euro zone bond yields dip, data shows wage growth slowed in Q4

February 22, 2024 | benzinga.com

Nektar Therapeutics Stock (NASDAQ:NKTR) Insider Trades

February 20, 2024 | finance.yahoo.com

Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know

January 22, 2024 | finance.yahoo.com

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

January 22, 2024 | markets.businessinsider.com

DiaMedica Appoints Lorianne Masuoka As Chief Medical Officer

January 3, 2024 | finance.yahoo.com

Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA

December 30, 2023 | finance.yahoo.com

Following a 75% decline over last year, recent gains may please Nektar Therapeutics (NASDAQ:NKTR) institutional owners

See More Headlines

Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/04/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:NKTR
CUSIP: 64026810
CIK: 906709
Web: www.nektar.com
Phone: (415) 482-5300
Fax: 415-339-5300
Employees: 137
Year Founded: 1990

Price Target and Rating

Average Stock Price Target: $3.50
High Stock Price Target: $6.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +182.3%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-276,060,000.00
Net Margins: -306.31%
Pretax Margin: -306.54%
Return on Equity: -96.80%
Return on Assets: -37.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.45
Quick Ratio: 6.14

Sales & Book Value

Annual Sales: $90.12 million
Price / Sales: 2.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.69 per share
Price / Book: 1.80

Miscellaneous

Outstanding Shares: 183,620,000
Free Float: 177,981,000
Market Cap: $227.69 million
Optionable: Optionable
Beta: 0.90

Social Links

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Howard W. Robin (Age 71)
CEO, President & Director
Comp: $1.83M
Mr. Mark A. Wilson (Age 52)
Senior VP, Chief Legal Officer & Secretary
Comp: $749.99k
Dr. Jonathan Zalevsky Ph.D. (Age 49)
Chief Research & Development Officer
Comp: $1.25M
Ms. Sandra A. Gardiner (Age 58)
Interim Chief Financial Officer
Vivian Wu
Director of Investor Relations & Corporate Affairs
Mr. Robert Bacci
Senior Vice President of Human Resources & Facilities Operations
Ms. Jennifer Ruddock
Chief Business Officer
Dr. Mary Tagliaferri L.Ac. (Age 58)
M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NKTR Stock Analysis - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View NKTR analyst ratings or view top-rated stocks.
What is Nektar Therapeutics' stock price target for 2024?: 5 analysts have issued twelve-month target prices for Nektar Therapeutics' stock. Their NKTR share price targets range from $1.00 to $6.00. On average, they expect the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 182.3% from the stock's current price.
View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts.
How have NKTR shares performed in 2024?: Nektar Therapeutics' stock was trading at $0.5650 at the start of the year. Since then, NKTR shares have increased by 119.5% and is now trading at $1.24.
View the best growth stocks for 2024 here.
When is Nektar Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our NKTR earnings forecast.

How were Nektar Therapeutics' earnings last quarter?: Nektar Therapeutics (NASDAQ:NKTR) posted its earnings results on Monday, March, 4th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.01. The biopharmaceutical company had revenue of $23.89 million for the quarter, compared to analysts' expectations of $17.09 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 96.80% and a negative net margin of 306.31%. During the same quarter in the prior year, the business earned ($0.32) earnings per share.
What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?: 46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.
What other stocks do shareholders of Nektar Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).
How do I buy shares of Nektar Therapeutics?: Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NKTR) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial